Search for a trial | Research with human participants

2 results

Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer

Approved WMOCompleted

To evaluate whether Telisotuzumab Vedotin improves response rate and survival in participants who are c-Met+ with NSCLC. For the additional monotherapy cohort :Primary objective is to evaluate the safety and tolerability of telisotuzumab vedotin…

A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer

Approved WMORecruiting

This study has been transitioned to CTIS with ID 2023-505749-14-00 check the CTIS register for the current data. The purpose of this study is to determine if telisotuzumab vedotin works better than docetaxel and to assess how safe telisotuzumab…